Bringing together more than 90 bold scientists across the fields of computational biology, protein engineering, and RNA guide design, we have relentlessly focused on overcoming the existing limitations of CRISPR-based genome editing to specifically and effectively target any gene, while eliminating off-target effects. Our technology is so specific that we can cut one allele at a time, opening new potential routes to treat difficult genetic indications like autosomal dominant diseases.